Sort By
-
Cory Abate-Shen, PhD
A Novel Human-to-Mouse-to-Human Approach for the Elucidation..
Cory Abate-Shen, PhD
Award:
First-time PCF Award Recipient
University:
Columbia University Medical Center
-
Gustavo Ayala, MD
Targeting Neurogenesis in Prostate Cancer The prostate..
-
Joshi Alumkal
In previous studies, Dr. Joshi Alumkal has..
Joshi Alumkal
The 2011 John F. Scarpa – PCF Young Investigator Award
Joshi Alumkal, MD:
Oregon Health & Science University Knight Cancer Institute
Mentors:
Joe Gray, PhD and Tomasz Beer, MD
-
Gerhardt Attard
Dr. Attard earned an MD degree from..
Gerhardt Attard
The 2008 Susan and James Blair – PCF Young Investigator Award
Gerhardt Attard, MD, PhD:
The Institute for Cancer Research – London, UK
-
Mohamed S. Arredouani
Dr. Arredouani earned a BS Degree in..
Mohamed S. Arredouani
The 2008 Michael Milken Scholar – PCF Young Investigator Award
Mohamed S. Arredouani, PhD:
Beth Israel Deaconess Hospital – Boston, MA
-
Andrew Armstrong
Dr. Armstrong earned a BS in Biomedical..
Andrew Armstrong
The 2008 Goergen Foundation – PCF Young Investigator Award
Andrew Armstrong, MD, ScM:
Duke University – Durham, NC
-
Vivek Arora
Preclinical assessment of mechanisms of resistance to..
Vivek Arora
2013 Millennium: The Takeda Oncology Company
Vivek Arora, MD, PhD:
Washington University
Mentor:
Charles Sawyers, MD
Project Title:
Defining strategies to overcome enzalutamide (Xtandi) resistance
-
Irfan Asangani
The organization of DNA into super-structures is..
Irfan Asangani
2013 The Republic of Tea-PCF Young Investigator
Irfan Asangani, PhD:
University of Michigan
Mentor:
Arul Chinnaiyan, MD, PhD
Project Title:
Characterization and therapeutic targeting of MMSET in prostate cancer
-
Emmanuel Antonarakis
Understanding resistance to new treatments for advanced,..
Emmanuel Antonarakis
2013 Steve Wynn-PCF Young Investigator
Emmanuel Antonarakis, MD:
Johns Hopkins University School of Medicine
Mentors:
Michael Carducci, MD and Jun Luo, PhD
Project Title:
Understanding mechanisms of response and resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer, by interrogation of tumor biopsies for androgen receptor splice variants.
-
Syed Adnan Ali
Over 1 million prostate biopsies are performed..
Syed Adnan Ali
2013 LeFrak Family-PCF Young Investigator
Syed Adnan Ali, MD:
Mount Sinai School of Medicine
Mentor:
Ashutosh Tewari, MD
Project Title:
Intratumor Heterogeneity (ITH) in Prostate Cancer
-
Rahul Aggarwal
The development of androgen axis inhibitors Zytiga®..
Rahul Aggarwal
Rahul Aggarwal, MD:
University of California, San Francisco
Mentor:
Eric Small, MD
Proposal Title:
Targeting MYC-Driven Cell Cycle Progression in Neuroendocrine Prostate Cancer with Gallium Citrate PET as a Novel Biomarker of MYC Transcriptional Activity
2015 John Paulson–PCF Young Investigator
-
Wassim Abida
Genomic profiling of primary and metastatic treatment-resistant..
Wassim Abida
Wassim Abida, MD, PhD :
Memorial Sloan Kettering Cancer Center
Mentors:
Howard Scher, MD; Charles Sawyers, MD
Proposal Title:
Investigating Treatment Selection and Resistance Using Prostate Cancer Genomics
2015 David H. Koch–PCF Young Investigator
